Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cathy Kelly

Senior Writer

Washington, DC
Cathy Kelly has been covering reimbursement and market access news for more than a decade for "The Pink Sheet" and other publications that are now part of Informa's pharmaceutical intelligence resources. Her expertise spans legislative, regulatory and public policy topics as well as coverage trends in public and private insurance markets. Cathy is especially interested in following the ongoing transformation of the US health care system and its effect upon major stakeholders in the biopharma industry. She is based in Washington D.C.
Set Alert for Articles By Cathy Kelly

Latest From Cathy Kelly

One-Third Of Payers Preferred Biosimilars Over Reference Drug in 2017

As biosimilar uptake remains modest, rebate amounts trend upward for medical benefit drugs, according to latest MagellanRx drug trend report.

Biosimilars Pricing Strategies

340B Hospitals May Be Losing Transparency Debate In Congress

Biopharma industry's arguments on rebate pass-through to patients appear to carry the day at Senate HELP Committee hearing.

Pricing Debate Legislation

Oncologists Charge More Than Other Specialties For Same Drugs, Study Finds

Oncologists charge at least 50% more for Lupron and Aranesp than do urologists or nephrologists, researchers with Johns Hopkins and Memorial Sloan Kettering found.

Pricing Debate Policy

Presidential Cancer Panel's Drug Value, Affordability Recommendations Align With Industry Views

Panel recommends National Academies of Sciences evaluate value frameworks like ICER, identify limitations and strengths and, if necessary, develop a new approach.

Policy Pricing Debate

Express Scripts Combination With Cigna's PBM Could Reverse Deficit From Losing Anthem

Merger could restore number of covered lives PBM will lose once its contract with Anthem expires, but there is also risk of alienating current health plan clients who don't want to contract with a competitor.

Pharmacy Benefit Management M & A

Biosimilars Need Better Reimbursement, Not 'Kabuki' Coverage, Gottlieb Tells Insurers

Rebate arrangements that block biosimilar uptake under guise of lowering costs do patients no favors, US FDA Commissioner says at AHIP policy conference.
Pricing Debate Biosimilars
See All